3713. 25. Leonard JP, Schuster SJ, Emmanouilides C, Couture F, Teoh N, et al. Tough comprehensive responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer 113: 27142723. 26. Raetz EA, Cairo MS, Borowitz MJ, Blaney SM, Krailo MD, et al. Chemoimmunotherapy reinduction with epratuzumab in youngsters with acute lymphoblastic leukemia in marrow relapse: a Children’s Oncology Group Pilot Study. J Clin Oncol 26: 37563762. 27. Steinfeld SD, Tant L, Burmester GR, Teoh NK, Wegener WA, et al. Epratuzumab in main Sjogren’s syndrome: an open-label phase I/II study. Arthritis Res Ther 8: R129. 28. Dorner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, et al. Initial clinical trial of epratuzumab for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther eight: R74. 29. Wallace DJ, Gordon C, Strand V, Hobbs K, Petri M, et al. Efficacy and safety of epratuzumab in individuals with moderate/severe flaring systemic lupus erythematosus: final results from two randomized, double-blind, Madrasin site placebo-controlled, multicentre research and follow-up. Rheumatology. 52: 13131322. 30. Wallace DJ, Kalunian K, Petri MA, Strand V, Houssiau FA, et al. Efficacy and safety of epratuzumab in individuals with moderate/severe active 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum 
Dis. Wallace D, Kalunian K, Petri M, Strand V, Kilgallen B, et al. Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to serious systemic lupus erythematosus: Benefits from EMBLEMTM, a phase IIb study. Ann Rheum Dis: 558. Rossi EA, Goldenberg DM, Michel R, Rossi DL, Wallace DJ, et al. Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab. Blood 122: 30203029. Joly E, Hudrisier D What’s trogocytosis and what exactly is its objective Nat Immunol 4: 815. Beum PV, Kennedy AD, Williams ME, Lindorfer MA, Taylor RP The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol 176: 26002609. Ahmed KA, Xiang J Mechanisms of cellular communication via intercellular protein transfer. J Cell Mol Med 15: 14581473. Davis DM Intercellular transfer of cell-surface proteins is popular and can have an effect on several stages of an immune response. Nat Rev Immunol 7: 238243. Rechavi O, Goldstein I, Kloog Y Intercellular exchange of proteins: the immune cell habit of sharing. FEBS Lett 583: 17921799. Sprent J Swapping molecules through cell-cell interactions. Sci STKE. 2005: e8. Ahmed KA, Munegowda MA, Xie Y, Xiang J Intercellular trogocytosis plays an essential part in modulation of immune responses. Cell Mol Immunol five: 261269. Caumartin J, Lemaoult J, Iloprost Carosella ED Intercellular exchanges of membrane patches highlight the subsequent amount of immune plasticity. 
Transpl. Immunol 17: 2022. Lemaoult J, Caumartin J, Daouya M, Favier B, Le RS, et al. Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood 109: 20402048. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis issue therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evalua.3713. 25. Leonard JP, Schuster SJ, Emmanouilides C, Couture F, Teoh N, et al. Tough comprehensive responses from therapy with combined epratuzumab and rituximab: final benefits from an international multicenter, phase two study in recurrent, indolent, non-Hodgkin lymphoma. Cancer 113: 27142723. 26. Raetz EA, Cairo MS, Borowitz MJ, Blaney SM, Krailo MD, et al. Chemoimmunotherapy reinduction with epratuzumab in youngsters with acute lymphoblastic leukemia in marrow relapse: a Children’s Oncology Group Pilot Study. J Clin Oncol 26: 37563762. 27. Steinfeld SD, Tant L, Burmester GR, Teoh NK, Wegener WA, et al. Epratuzumab in main Sjogren’s syndrome: an open-label phase I/II study. Arthritis Res Ther 8: R129. 28. Dorner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, et al. Initial clinical trial of epratuzumab for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther eight: R74. 29. Wallace DJ, Gordon C, Strand V, Hobbs K, Petri M, et al. Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: benefits from two randomized, double-blind, placebo-controlled, multicentre studies and follow-up. Rheumatology. 52: 13131322. 30. Wallace DJ, Kalunian K, Petri MA, Strand V, Houssiau FA, et al. Efficacy and security of epratuzumab in patients with moderate/severe active 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. systemic lupus erythematosus: final results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis. Wallace D, Kalunian K, Petri M, Strand V, Kilgallen B, et al. Epratuzumab demonstrates clinically meaningful improvements in sufferers with moderate to serious systemic lupus erythematosus: Final results from EMBLEMTM, a phase IIb study. Ann Rheum Dis: 558. Rossi EA, Goldenberg DM, Michel R, Rossi DL, Wallace DJ, et al. Trogocytosis of several B-cell surface markers by CD22 targeting with epratuzumab. Blood 122: 30203029. Joly E, Hudrisier D What exactly is trogocytosis and what exactly is its purpose Nat Immunol four: 815. Beum PV, Kennedy AD, Williams ME, Lindorfer MA, Taylor RP The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol 176: 26002609. Ahmed KA, Xiang J Mechanisms of cellular communication through intercellular protein transfer. J Cell Mol Med 15: 14581473. Davis DM Intercellular transfer of cell-surface proteins is typical and can impact quite a few stages of an immune response. Nat Rev Immunol 7: 238243. Rechavi O, Goldstein I, Kloog Y Intercellular exchange of proteins: the immune cell habit of sharing. FEBS Lett 583: 17921799. Sprent J Swapping molecules for the duration of cell-cell interactions. Sci STKE. 2005: e8. Ahmed KA, Munegowda MA, Xie Y, Xiang J Intercellular trogocytosis plays an important role in modulation of immune responses. Cell Mol Immunol 5: 261269. Caumartin J, Lemaoult J, Carosella ED Intercellular exchanges of membrane patches highlight the subsequent degree of immune plasticity. Transpl. Immunol 17: 2022. Lemaoult J, Caumartin J, Daouya M, Favier B, Le RS, et al. Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood 109: 20402048. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Outcomes of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evalua.